Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification

International Journal of Oncology

Volumn 41, Issue 2, 2012, Pages 551-558

  Tomioka, Hideo ^a   Mukohara, Toru ^a,b   Kataoka, Yu ^a   Ekyalongo, Roudy Chiminch ^a   Funakoshi, Yohei ^a   Imai, Yasuo ^c   Kiyota, Naomi ^a   Fujiwara, Yutaka ^a,d   Minami, Hironobu ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY HOSPITAL   (Japan)

^c DOKKYO MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Everolimus; Fluorouracil; Gastric cancer; HER2; Trastuzumab

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; S6 KINASE; TRASTUZUMAB;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; IN VITRO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; PACLITAXEL; QUINAZOLINES; RECEPTOR, ERBB-2; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84863565765     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1485     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006. (Pubitemid 46655601)
3. Sue - Ling HM, Johnston D, Martin IG, et al: Gastric cancer: a curable disease in Britain. BMJ 307: 591-596, 1993.
4. Menges M and Hoehler T: Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 135: 29-38, 2009.
5. Ajani JA: Evolving chemotherapy for advanced gastric cancer. Oncologist 10 (Suppl 3): 49-58, 2005.
6. Slamon DJ, Leyland - Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
7. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
8. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small - cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
9. Yokota J, Yamamoto T, Miyajima N, et al: Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2: 283-287, 1988. (Pubitemid 18085309)
10. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008. (Pubitemid 351724903)
11. Tanner M, Hollmen M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005. (Pubitemid 40309309)
12. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H and Tahara E: Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232, 1992. (Pubitemid 23030031)
13. Hattori Y, Itoh H, Uchino S, et al: Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2: 1373-1381, 1996. (Pubitemid 26299437)
14. Ueda T, Sasaki H, Kuwahara Y, et al: Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 59: 6080-6086, 1999. (Pubitemid 30035624)
15. Tsujimoto H, Sugihara H, Hagiwara A and Hattori T: Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch 431: 383-389, 1997. (Pubitemid 27519371)
16. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
17. Neve RM, Lane HA and Hynes NE: The role of overexpressed HER2 in transformation. Ann Oncol 12 (Suppl 1): 9-13, 2001.
18. Yokoyama H, Ikehara Y, Kodera Y, et al: Molecular basis for sensitivity and acquired resistance to gefitinib in HER2- overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 95: 1504-1513, 2006. (Pubitemid 44863353)
19. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N and Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 27: 681-685, 2005.
20. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM and Hynes NE: ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223, 2000. (Pubitemid 30215033)
21. Abramoff MD, Magalhaes PJ and Ram SJ: Image processing with ImageJ. Biophotonics Int 11: 36-42, 2004.
22. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R and Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739-749, 2004. (Pubitemid 38771819)
23. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
24. Gong SJ, Jin CJ, Rha SY and Chung HC: Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 214: 215-224, 2004. (Pubitemid 39207983)
25. Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 50: 767-777, 2000.
26. Mita H, Toyota M, Aoki F, et al: A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild - type KRAS in downstream signaling and cancer cell growth. BMC Cancer 9: 198, 2009.
27. Sharma P and Halayko AJ: Emerging molecular targets for the treatment of asthma. Indian J Biochem Biophys 46: 447-460, 2009.
28. Kim SY, Kim HP, Kim YJ, et al: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32: 89-95, 2008. (Pubitemid 351176065)
29. Tanizaki J, Okamoto I, Takezawa K, et al: Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 9: 1198-1207, 2010.
30. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M and Minami H: Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21: 255-262, 2010.
31. Harada H, Andersen JS, Mann M, Terada N and Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 98: 9666-9670, 2001. (Pubitemid 32769360)
32. Doi T, Muro K, Boku N, et al: Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28: 1904-1910, 2010.
33. Danilkovitch-Miagkova A and Zbar B: Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109: 863-867, 2002. (Pubitemid 34275106)
34. Lim T, Lee J, Lee DJ, et al: Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol 68: 255-262, 2011.